Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan-Feb;31(1):58-69.
doi: 10.1177/1091581811425256. Epub 2012 Jan 20.

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs

Padmaja Yerramilli-Rao  1 , M Flint Beal, Dai Watanabe, Karl Kieburtz, Elisabeth A de Blieck, Mitsuaki Kitano, Kazunori Hosoe, Iwao Funahashi, Merit E Cudkowicz
Affiliations

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs

Padmaja Yerramilli-Rao et al. Int J Toxicol. 2012 Jan-Feb.

Abstract

To support phase III testing of coenzyme Q10 (CoQ₁₀) in humans, we conducted pharmacokinetic and toxicology studies in beagle dogs. Following single gavage administration of CoQ₁₀ at 600, 1200, 1800, or 2400 mg/kg per d no obvious dose response was observed in maximum concentration (C(max)) or area under the curve (AUC) versus time curve at the 3 highest dosages. In a repeated-dose study of CoQ₁₀ at 600, 1200, 1800, or 2400 mg/kg per d for 4 weeks, CoQ₁₀ reached steady state in plasma by 2 weeks at all dosages. Both C (max) and AUC increased with increasing dosage of CoQ₁₀. The highest plasma levels were recorded at 1800 mg/kg per d. In a 39-week chronic toxicity study of CoQ₁₀ at 1200 and 1800 mg/kg per d or placebo, CoQ₁₀ reached steady state in plasma by 13 weeks. Behaviors, blood chemistries, and detailed histopathology were normal. No deaths occurred. These results support the use of a 2400 mg/d dosage of CoQ₁₀ in human clinical trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1. AUC values in dogs administered a single dose of CoQ10 at 600, 1200, 1800 and 2400mg/kg by gavage
Bars denote mean value and dots denote individual values of two animals per dosage group, except in the 600mg/kg dosage group where one animal showed abnormal plasma concentration, likely due to a dosing error (value not shown).
Figure 2
Figure 2. AUC values in dogs administered 600, 1200, 1800 and 2400mg/kg of CoQ10 daily by gavage for 28 consecutive days
Bars denote mean values and dots denote individual values of two animals per dosage group.
Figure 3
Figure 3. Cmax Values at Day 1 and at Week 39 in Male and Female Dogs Administered Placebo, 1200mg/kg or 1800mg/kg of CoQ10 daily by gavage for 39 weeks
Cmax was greater at Week 39 than at Day 1. Bars denote mean values and dots denote individual values of four animals per dosage group.
Figure 4
Figure 4. Tmax Values at Day 1 and at Week 39 in Male and Female Dogs Administered Placebo, 1200mg/kg or 1800mg/kg of CoQ10 daily by gavage for 39 weeks
Tmax was shorter at Week 39 than at Day 1 Bars denote mean values and dots denote individual values of four animals per dosage group.
Figure 5
Figure 5. AUC Values at Day 1 and at Week 39 in Male and Female Dogs Administered Placebo, 1200mg/kg or 1800mg/kg of CoQ10 daily by gavage for 39 weeks
AUC was greater at Week 39 than at Day 1. Bars denote mean values and dots denote individual values of four animals per dosage group.
See this image and copyright information in PMC

References

    1. [accessed July 2011]; ClinicalTrials.gov Identifiers NCT00608881 and NCT00740714.
    1. Lehninger AL. The molecular organization of mitochondrial membranes. Adv Cytopharmacol. 1971;1:199–208. - PubMed
    1. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci. 2003;991:120–131. - PubMed
    1. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002;22(5):1592–1599. - PMC - PubMed
    1. Schilling G, Coonfield ML, Ross CA, et al. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001;315(3):149–153. - PubMed

Publication types

LinkOut - more resources